BASF
be abandoned due to the lack of a regional center ,” said Furlan .
The investment of over 1 million euros in Jacareí , São Paulo state , includes specialized technology , providing the pharmaceutical industry active ingredients such as ibuprofen and Omega-3 , as well as excipients for a wide variety of pharmaceutical applications .
According to Furlan , “ Today more than 80 percent of BASF ’ s pharmaceutical development projects involve direct cooperation with our customers , adapted to specific characteristics and needs of their formulations . The laboratory will strengthen our customer service the South American market .”
In addition to accelerating the launch of new products to the market , the new center also has the function of helping to find innovative and effective solutions for the customers ’ challenges in the region , such as solubility , coating , optimizing and reduction of variability productivity .
With cutting-edge equipment for pill manufacturing , as well as quick and easy transfer to industrial scale , the laboratory uses extrusion technology by fusion ( Hot-Melt- Extrusion ), recognized for its potential to increase bioavailability of pharmaceutical actives with lower solubility .
“ The laboratory is designed to stimulate innovation , as an open area with latest technology equipment at hand that allows the use of different simultaneous technologies . This elevates the productivity of our industries , as
“ Today more than 80 percent of BASF ’ s pharmaceutical development projects involve direct cooperation with our customers , adapted to specific characteristics and needs of their formulations .”
– Fernanda Furlan , Business Manager of BASF ’ s Pharma business unit for South America
56 December 2015